Search Results

•New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases •Delivering on Company’s plans for increased U.S. investment, $2 billion+ advanced biologics facility will add more than 5,000 high-wage manufacturing and construction jobs in North Carolina. •Investment will create an estimated economic impact of $3 billion statewide during first 10 years of site operation

Investment builds on almost 140-year legacy of improving and saving lives and supporting American jobs Includes four planned new manufacturing facilities, with ground-breaking today in North Carolina on $2 billion+ facility Total Company U.S. economic impact estimated to be more than $100 billion per year

TREMFYA® is the only IL-23i to demonstrate clinical remission and endoscopic response, both at one year, with a fully subcutaneous induction regimen Supported by data from the GALAXI study, TREMFYA® is the only IL-23i to show superiority versus STELARA® in all pooled endoscopic endpoints within a double-blinded registrational trial TREMFYA® approval in Crohn’s disease builds upon recent ulcerative colitis FDA approval, marking the fourth indication for this dual-acting IL-23i in the U.S.

Median overall survival improvement projected to exceed one year with much-anticipated overall survival analysis showing statistically superior result versus osimertinib Preventative dermatologic regimen meets primary endpoint and enhances patient experience

Sjögren’s disease (SjD) is a prevalent, debilitating autoantibody disease with no FDA-approved advanced treatments The Company is actively enrolling patients in the Phase 3 DAFFODIL study This marks the fourth nipocalimab FDA Fast Track designation

As the Founding Sponsor, J&J contributes $1 million to accelerate the creation of industry-aligned curricula and state-of-the-art training facilities at three leading New Jersey community colleges

Next-generation NVIDIA-powered AI navigation software elevates MONARCHTM Platform for Robotically Assisted Bronchoscopy

Building on last year’s momentum of 18 FDA 510(k) Clearances and 45 global product launches, the company accelerates innovation across joint reconstruction, trauma, spine, and more

Topline results also show investigational targeted oral peptide icotrokinra achieved clinical remission rates up to 30.2% at Week 12 and a favorable safety profile in Phase 2b ANTHEM-UC study Clinical response and remission rates continued to improve through Week 28, building on strong data recently reported for the plaque psoriasis Phase 3 program Icotrokinra demonstrates potential to offer therapeutic benefit and tolerability with a once daily oral treatment

Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with investigational icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD Topline results from Phase 3 ICONIC-ADVANCE 1&2 studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO These results pave the way to initiate the first-ever head-to-head study seeking to demonstrate the superiority of a pill versus injectable biologic in moderate-to-severe plaque PsO